Table 4.
EC50 (μg/mL) of antitumor activity of compounds 1–4, 6 and the fungal extract against five cell lines
| Compound/extract | EC50 μg/mL |
||||
|---|---|---|---|---|---|
| HEPG2 | HELA | MCF7 | A549 | PC3 | |
|
| |||||
| RF-3192C (1) | NTa | NT | 47 | 48.7 | NT |
| Orlandin (2) | 45 | - | NT | >8.2b | >8.2b |
| Fonscein B (3) | 29.5 | - | NT | NT | NT |
| TMC-256A1 (4) | 30 | - | NT | NT | NT |
| Cerebroside A (6) | 20.8 | - | NT | >58b | >58b |
| Crude extract | 9.34 | - | NT | NT | NT |
| Doxorubicin | 4.28 | 1.45 | 17.44 | 8.64 | NT |
(-) = no activity investigated
a
NT = not tested
b
Compounds 2 and 6 were tested against A549 and PC3 cell lines in triplicates using a single dose experiment at 80 μM concentration (Supplementary Information, Fig. S3A). For more details, see Supplementary Information, Table S4 and Figs S2–3